Dubuque Bank & Trust Co. boosted its position in Celgene Corporation (NASDAQ:CELG) by 5.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,367 shares of the biopharmaceutical company’s stock after buying an additional 2,740 shares during the period. Celgene Corporation comprises about 1.4% of Dubuque Bank & Trust Co.’s holdings, making the stock its 22nd largest position. Dubuque Bank & Trust Co.’s holdings in Celgene Corporation were worth $6,411,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Private Asset Management Inc. increased its position in Celgene Corporation by 3.2% in the first quarter. Private Asset Management Inc. now owns 1,832 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 57 shares in the last quarter. Capital Investment Services of America Inc. bought a new position in Celgene Corporation during the first quarter valued at $203,000. Bridges Investment Management Inc. increased its position in Celgene Corporation by 2.8% in the first quarter. Bridges Investment Management Inc. now owns 134,645 shares of the biopharmaceutical company’s stock valued at $16,755,000 after buying an additional 3,622 shares in the last quarter. Chevy Chase Trust Holdings Inc. increased its position in Celgene Corporation by 3.2% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 720,403 shares of the biopharmaceutical company’s stock valued at $89,640,000 after buying an additional 22,612 shares in the last quarter. Finally, Burns J W & Co. Inc. NY increased its position in Celgene Corporation by 44.8% in the first quarter. Burns J W & Co. Inc. NY now owns 43,134 shares of the biopharmaceutical company’s stock valued at $5,367,000 after buying an additional 13,343 shares in the last quarter. 78.41% of the stock is currently owned by institutional investors and hedge funds.

Celgene Corporation (CELG) traded up 0.3681% during midday trading on Friday, reaching $130.8499. The company’s stock had a trading volume of 1,652,311 shares. The stock’s 50-day moving average price is $134.23 and its 200 day moving average price is $124.17. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The firm has a market capitalization of $102.37 billion, a PE ratio of 40.5233 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s revenue was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.44 EPS. Equities analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/dubuque-bank-trust-co-increases-stake-in-celgene-corporation-nasdaqcelg/1475059.html.

CELG has been the topic of several analyst reports. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their target price for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Leerink Swann reissued an “outperform” rating and set a $160.00 target price (up previously from $150.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Argus raised Celgene Corporation from a “hold” rating to a “buy” rating and boosted their target price for the company from $96.93 to $160.00 in a research report on Monday, July 31st. Credit Suisse Group set a $148.00 target price on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. Finally, Cann reissued a “buy” rating on shares of Celgene Corporation in a research report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $147.00.

In related news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the sale, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director James J. Loughlin sold 18,500 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $133.57, for a total value of $2,471,045.00. Following the completion of the sale, the director now directly owns 32,877 shares in the company, valued at approximately $4,391,380.89. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,255 shares of company stock worth $31,377,042. 0.95% of the stock is owned by corporate insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.